**SUPPLEMENTARY TABLES**

**Supplementary Table 1.** Comparison of transaminase levels, non-invasive scores (Cohort I) and transient elastography (Cohort II) among lean patients (BMI<25kg/m²) without NAFLD, lean patients with NAFLD, overweight patients (BMI 25-30kg/m²) with NAFLD and obese patients (BMI ≥30kg/m²) with NAFLD.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Cohort I** | **Lean w/o NAFLD, n=892** | **Lean NAFLD,** **n=205** | **Overweight NAFLD, n=636** | **Obese NAFLD, n=505** | ***P* value** |
|
| Fib-4 score | 1.22±0.45 | 1.42±0.76 | 1.38±0.88 | 1.47±1.10 | *<0.001* |
|  | >3.25 | 0 (0.0%) | 4 (2.1%) | 13 (2.1%) | 18 (3.7%) | *<0.001* |
| ALT/ULN | 0.46±0.23 | 0.69±0.73 | 0.70±0.65 | 0.76±0.46 | *<0.001* |
| AST/ULN | 0.59±0.18 | 0.76±0.53 | 0.73±0.44 | 0.76±0.42 | *<0.001* |
| GGT/ULN | 0.71±0.88 | 1.29±1.98 | 1.32±1.50 | 1.41±2.30 | *<0.001* |
| **Cohort II** | **Lean w/o NAFLD, n=254** | **Lean NAFLD,** **n=169** | **Overweight NAFLD, n=317** | **Obese NAFLD, n=154** |  |
| LSM, kPa | 4.5±1.3 | 4.7±2.0 | 5.2±2.1 | 5.9±6.0 | *<0.001* |
|  | ≥8kPa | 0 (0.0%) | 5 (3.0%) | 15 (5.7%) | 19 (12.5%) | *<0.001* |
| CAP, dB/m | 208±33 | 286±31 | 300±35 | 327±42 | *<0.001* |
|  | >280dB/m | - | 86 (50.6%) | 211 (66.6%) | 126 (81.8%) | *<0.001* |
| ALT/ULN | 0.46±0.17 | 0.51±0.25 | 0.64±0.46 | 0.71±0.39 | *<0.001* |
| AST/ULN | 0.51±0.13 | 0.52±0.27 | 0.52±0.29 | 0.54±0.21 | *0.552* |
| GGT/ULN | 0.47±0.32 | 0.62±0.86 | 0.78±0.87 | 0.83±0.81 | *<0.001* |

Fib-4 score applying a cut-off of >3.25 was used to diagnose advanced fibrosis (≥F3)[1].

**REFERENCES USED IN SUPPLEMENTARY MATERIAL**

1 McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. *Gut* 2010; **59:** 1265-9.